Comparison of <font color="red">propofol_4</font> <font color="red">,_4</font> <font color="red">droperidol_4</font> <font color="red">,_4</font> <font color="red">and_2</font> <font color="red">metoclopramide_4</font> for prophylaxis of postoperative nausea and vomiting after breast cancer <font color="red">surgery_1</font> <font color="red">:_1</font> a prospective , randomized , double - blind , <font color="red">placebo_4</font> <font color="red">-_4</font> <font color="red">controlled_1</font> study in Japanese patients . 
<br>
<br> BACKGROUND <font color="red">Breast_1</font> <font color="red">cancer_1</font> <font color="red">surgery_1</font> performed with the patient under general anesthesia has been associated with a relatively high incidence of postoperative nausea and vomiting ( PONV ) . Between 60% and 80% of patients who undergo <font color="red">mastectomy_1</font> ( <font color="red">with_1</font> <font color="red">axillary_1</font> <font color="red">dissection_1</font> <font color="red">)_1</font> experience PONV . We previously reported that <font color="red">propofol_1</font> at a subhypnotic dose of 0.5 mg / kg was more effective than <font color="red">placebo_2</font> in preventing PONV in women who undergo <font color="red">mastectomy_1</font> <font color="red">._1</font> 
<br> OBJECTIVE The purpose of this study was to compare the efficacy of a subhypnotic dose of <font color="red">propofol_2</font> <font color="red">with_1</font> <font color="red">the_1</font> <font color="red">conventional_2</font> <font color="red">antiemetics_2</font> <font color="red">droperidol_3</font> <font color="red">and_2</font> <font color="red">metoclopramide_3</font> for the prophylaxis of PONV after <font color="red">breast_1</font> <font color="red">cancer_1</font> <font color="red">surgery_1</font> in Japanese patients . 
<br> METHODS In this prospective , randomized , double - blind , <font color="red">placebo_3</font> <font color="red">-_3</font> <font color="red">controlled_1</font> study , Japanese women were randomized to 1 of 4 groups to receive IV administration of <font color="red">propofol_5</font> <font color="red">0.5_2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">kg_2</font> <font color="red">,_2</font> <font color="red">droperidol_5</font> <font color="red">20_2</font> <font color="red">microg_2</font> <font color="red">/_2</font> <font color="red">kg_2</font> <font color="red">,_2</font> <font color="red">metoclopramide_5</font> <font color="red">0.2_2</font> <font color="red">mg_2</font> <font color="red">/_2</font> <font color="red">kg_2</font> <font color="red">,_2</font> <font color="red">or_2</font> <font color="red">placebo_5</font> <font color="red">(_1</font> <font color="red">isotonic_1</font> <font color="red">saline_1</font> <font color="red">)_1</font> immediately after skin suture . <font color="red">A_1</font> <font color="red">standard_1</font> <font color="red">general_2</font> <font color="red">anesthetic_2</font> <font color="red">technique_2</font> <font color="red">,_2</font> <font color="red">including_1</font> <font color="red">sevoflurane_2</font> <font color="red">and_1</font> <font color="red">air_1</font> <font color="red">in_1</font> <font color="red">oxygen_1</font> <font color="red">,_1</font> was used . All episodes of PONV during the first 24 hours after <font color="red">anesthesia_1</font> <font color="red">administration_1</font> were recorded by an investigator who was blinded to <font color="red">treatment_1</font> assignment . The investigator questioned the patients as to whether they experienced extrapyramidal symptoms . To maintain the integrity of the study results , none of the patients received preanesthetic medication . 
<br> RESULTS A total of 100 women ( mean [ SD ] age , 52 [ 7 ] years ; height , 154 [ 6 ] cm ; weight , 54 [ 7 ] kg ) were included in the study . Each study group comprised 25 patients . There were no significant differences between <font color="red">treatment_1</font> groups with regard to patient demographics , surgery type , or awakening time . The prevalences of PONV 0 to 24 hours after <font color="red">anesthesia_1</font> were 28% with <font color="red">propofol_3</font> ( P = 0.005 ) , 32% with <font color="red">droperidol_3</font> ( P = 0.011 ) , and 60% with <font color="red">metoclopramide_3</font> ( P = NS ) , compared with <font color="red">placebo_3</font> ( 68% ) . No significant difference in the prevalence of PONV was found between patients receiving <font color="red">propofol_3</font> and those receiving <font color="red">droperidol_3</font> <font color="red">,_3</font> and <font color="red">propofol_3</font> and <font color="red">droperidol_3</font> were associated with significantly lower prevalences of PONV compared with <font color="red">metoclopramide_3</font> ( P = 0.022 and P = 0.043 , respectively ) . Extrapyramidal symptoms were not reported in any of the groups . 
<br> CONCLUSIONS The prevalences of PONV were not significantly different between <font color="red">propofol_3</font> 0.5 mg / kg and <font color="red">droperidol_3</font> 20 microg / kg 0 to 24 hours after <font color="red">anesthesia_1</font> in this small , select group of Japanese women who underwent breast cancer surgery . The prevalences of PONV were significantly lower with <font color="red">propofol_3</font> <font color="red">and_1</font> <font color="red">droperidol_3</font> compared with <font color="red">metoclopramide_3</font> 0.2 mg / kg and <font color="red">placebo_3</font> <font color="red">._3</font>